Jyong Biotech Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MENS | -2.22% | +2.80% | -44.30% | — |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.19% | +7.44% | -40.86% | — |